Glioblastoma brain tumors harbor a small population of cancer stem cells that are resistant to conventional chemotherapeutic and radiation treatments, and are believed responsible for tumor recurrence and mortality. The identification of the epigenetic molecular mechanisms that control self-renewal of glioblastoma stem cells will foster development of targeted therapeutic approaches. The transcriptional repressor REST, best known for its role in controlling cell fate decisions in neural progenitor cells, may also be crucial for cancer stem cell self-renewal. Two novel mechanisms for regulating the stability of REST have recently been revealed: these involve the telomere-binding protein TRF2 and the ubiquitin E3 ligase SCFb-TrCP. Reduced TRF2 binding to REST, and increased SCFb-TrCP activity, target REST for proteasomal degradation and thereby inhibit cancer stem cell proliferation. Neurological side effects of treatments that target REST and TRF2 may be less severe than conventional brain tumor treatments because postmitotic neurons do not express REST and have relatively stable telomeres.
Introduction
Glioblastoma multiforme is the most common primary brain tumor in adults with an annual incidence of three per 100,000 [1] . The lethality of these tumors is underscored by a recent study which reported a one year survival rate of 18% and a two year survival rate of 3% for newly diagnosed glioblastomas [2] . Current standard-of-care therapies for glioblastoma include tumor resection, radiation and temozolomide (an alkylating agent) [3] . However, these conventional cytotoxic therapies have for the most part done little to improve overall patient survival, and there is a clear need for a better understanding of brain tumor biology so as to develop more effective therapies.
The failure to cure many cancers has been attributed to the fact that a minor subpopulation of cells can survive and initiate cancer recurrence after conventional chemotherapy or radiation treatments, even when the bulk of the tumor mass had been eliminated [4, 5] . Stem-like cells can be isolated from a wide variety of cancers, including leukemia, multiple myeloma, colon cancer and brain tumors, and this has led to the new concept of cancer stem cells or tumor initiation cells [6] [7] [8] [9] [10] [11] [12] . As with most cancers, glioblastomas are composed of a heterogeneous population of cells, and recent findings suggest that glioblastomas harbor cancer stem cells that are resistant to conventional therapies. In 2003, Singh et al. [13] reported the identification and purification of cancer stem cells from human brain tumors that possess a marked capacity for proliferation, self-renewal and differentiation. Other groups then reported that stem cells can be isolated from human adult glioblastomas that express the neural stem cell marker CD133, a surface antigen [14] [15] [16] (Figure 1 ). Like normal neural stem cells, glioblastoma stem cells exhibit a high capacity for self-renewal and, interestingly, remain capable of differentiating into neuron-and glia-like cells when exposed to differentiation signals in culture [16] [17] [18] . When grafted into mice CD133 + cells, but not CD133 -cells, are able to generate brain tumors that phenotypically recapitulate the patient's original tumor [19, 20] . Cancer stem cells derived from human glioblastoma surgical specimens and xenografts display resistance to radiation due to enhanced activity of the DNA damage checkpoint [21] . Considerable evidence therefore suggests a key role for cancer stem cells in tumor growth and recurrence of human glioblastomas.
Although it is as yet unknown whether cancer stem cells originate from transformed normal stem cells or from a different cell type, Hemmati et al. demonstrated that both normal and tumor-derived neurospheres display increased self-renewal capacity resulting from enhanced activity of the oncogene bmi-1 that encodes a member of the polycomb family of transcriptional factors involved in the epigenetic repression of differentiation and apoptosis [9] . In addition, cells isolated from cortical glial tumors contain neural stem-like cells expressing glial and neuronal markers and tumor-related genes including Notch [8] . In contrast, exposure of human brain cancer stem cells to astroglial fate-inducing factors such as BMP4 enforces terminal differentiation and renders the cells vulnerable to cytotoxic therapies [22] . It is therefore reasonable to suggest that the molecular mechanisms regulating the proliferation and differentiation of normal neural stem cells also determine 
